Abstract
INTRODUCTION
This market research report is an update of BCC' s original report on the
topic, published in 2001. BCC' s goal in conducting this study is to provide an
overview of the current and potential aspects of the global market for
cardiovascular drugs, devices, and diagnostics in the pharmaceutical and
biotechnology industries. The report determines the market size, market
leaders, and factors affecting the market of cardiovascular drugs, devices,
and diagnostics.
The overview of types of cardiovascular diseases and their prevalence is
examined along with sales figures over the 5-year period from 2007 to 2012.
Companies selling drugs, devices, and diagnostics are profiled; the factors
affecting markets for these products, and how those markets are likely to
change, are analyzed. Revenues have been broken down by the type of drug
products, devices implanted, and diagnoses performed.
Our key objective is to present a comprehensive analysis of the current market
and the future direction of cardiovascular drugs, devices, and diagnostics,
with an emphasis on newer products.
SCOPE OF STUDY
This report contains:
- Descriptions of various types of cardiovascular diagnostics such as in
vitro tests and in vivo imaging techniques, devices such as drug eluting
stents, and drugs such as Pfizer' s blockbuster Lipitor
- The current market status of cardiovascular diagnostics, devices and
drugs, along with trends and forecasts for growth over the next 5 years
- Technological issues including the latest developments and a thorough
patent analysis
- Analysis of the cardiovascular diagnostics, devices and drugs industry,
both from a market and application perspective
- Information about the major players in each market, including Medtronic
and Boston Scientific in devices, Sanofi-Aventis and BMS in drugs, and Abbott
in devices.
INFORMATION SOURCES
A comprehensive literature search was conducted. The literature included
technical newsletters and journals, as well as many other sources. The data
was collected through interviews and correspondence with various
pharmaceutical/biotechnical experts. Projections were based on estimates such
as the current number of end users, potential end users, likely unit prices,
rates of consumption, and market trends.
BCC surveyed many companies to obtain data for this study. Included were
manufacturers and end users of the pharmaceutical drugs through contract
manufacturing/research. Data were gathered from the industries; spoke with
officials or physicians of these industries; and consulted newsletters,
company literature, product literature, a host of technical articles,
journals, indexes, and abstracts. Exhaustive investigations of databases by
key terminology were done. In addition, data were compiled data from current
financial and trade information and government sources.
ANALYST CREDENTIALS
Shalini Shahani holds a Masters degree in Pharmaceutical Chemistry. Among the
research topics she has covered are studies on compounds of potential
pharmaceutical interest, including Ibuprofen and 2-Naphthyl Acetic Acid.
Shahani was awarded a Gold Medal by the Prime Minister of India for her work
and has worked with top companies in India and in the U.S. She has authored
several market research reports for BCC Research on various topics within the
chemical and pharmaceutical industries, including reagents for chromatography,
spectroscopy, advanced drug delivery, contract pharmaceutical manufacturing,
and chiral technology.
View Cart
